Specialist Updates 
Respiratory

Antifibrotic combo therapy reduces biomarkers in IPF

A subgroup analysis of the INSTAGE trial shows effects on biomarkers depend on the presence or absence of emphysema
Medicom Staff writer
0
11 September 2020
Save
ClosePlease login

AusDoc brings you the latest news from the European Respiratory Society Congress 2020.

A post-hoc analysis of results from the INSTAGE trial shows that treatment with a combination of nintedanib and sildenafil affects three biomarkers relating to idiopathic pulmonary fibrosis (IPF).

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .